The mechanisms of drug resistance in prostate cancer

Yang HE; Yang-guang LIU; Shan CEN; Jin-ming ZHOU.
Acta Pharmaceutica Sinica ; (12): 797-801, 2015.
Artículo en Zh | WPRIM | ID: wpr-257065

Documentos relacionados

  1. DNA Damage Promotes TMPRSS2-ERG Oncoprotein Destruction and Prostate Cancer Suppression via Signaling Converged by GSK3ß and WEE1.
  2. Treatment-emergent neuroendocrine prostate cancer with a germline <i>BRCA2</i> mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance.
  3. Resistance to prostate cancer treatments.
  4. Validation of a computerized decision support system to review pharmacotherapy treatment: scheduling guidelines.
  5. The biochemistry of disease: desperately seeking syzygy.
  6. Association of Interleukin-6 and Other Cytokines with Self-Reported Pain in Prostate Cancer Patients Receiving Chemotherapy.
  7. Aortite chez une patiente recevant une chimiothérapie.
  8. Emerging Therapies in Metastatic Prostate Cancer.
  9. Treatment effects in prostate cancer.
  10. Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis.